{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:59:30Z","timestamp":1778504370709,"version":"3.51.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Distinguishing porocarcinoma from squamous cell carcinoma (SCC) is clinically significant; however, differential diagnosis can often be challenging. This study sought to confirm the diagnostic utility of cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 immunohistochemistry in distinguishing porocarcinoma from SCC. Immunohistochemical analysis of cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 in 14 porocarcinomas and 22 SCCs was performed; the extents and intensities of expression of these markers were recorded. The statistical associations of the immunoexpression between porocarcinoma and SCC were analyzed using the Pearson \u03c7\n                    <jats:sup>2<\/jats:sup>\n                    test. Cytokeratin 19 was positive in 13 (92.9%) of 14 porocarcinomas, and for all the positive cases, staining was strong and evident in &gt;20% of the tumor cells. By contrast, 9 (40.9%) of 22 SCCs expressed cytokeratin 19 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0018), of which 6 showed extremely focal (\u226410% of the tumor cells) expression. Of the 14 porocarcinomas, 11 (78.6%) cases showed c-KIT positivity, whereas only 3 of 22 SCCs (13.6%) expressed c-KIT focally (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0001). In addition, BerEP4 immunostaining differed between porocarcinomas and SCCs (57.1% vs. 9.1%, respectively;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.0017). However, no significant difference between the groups was reported in terms of GATA3 expression (57.1% vs. 72.7%, respectively;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.3336). NUTM1 was expressed in 4\/14 (28.6%) porocarcinomas but not in the SCCs. Immunohistochemistry for cytokeratin 19, c-KIT, and BerEP4 could be helpful in distinguishing porocarcinomas from SCCs. In addition, NUTM1 immunoexpression is highly specific, although not sensitive, to porocarcinomas. GATA3 immunohistochemistry has no meaningful implications in the differential diagnosis of porocarcinoma and SCC.\n                  <\/jats:p>","DOI":"10.1097\/dad.0000000000001901","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T04:03:25Z","timestamp":1616731405000},"page":"781-787","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"43","author":[{"given":"Keisuke","family":"Goto","sequence":"first","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan;"},{"name":"Department of Pathology, Itabashi Central Clinical Laboratory, Tokyo, Japan;"},{"name":"Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan;"},{"name":"Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan;"},{"name":"Department of Dermatology, Hyogo Cancer Center, Akashi, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misawo","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Kainan Hospital, Yatomi, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shizuoka Cancer Center Hospital, Sunto, Japan; and"},{"name":"Department of Dermatology, Nara Medical University Hospital, Kashihara, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Muramatsu","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Naka","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Honma","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sugino","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"key":"R2-20250616","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.humpath.2011.10.005","article-title":"An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma","volume":"43","author":"Mahalingam","year":"2012","journal-title":"Hum Pathol."},{"key":"R3-20250616","first-page":"361","article-title":"The squamous variant of eccrine porocarcinoma: a clinicopathological study of 21 cases","volume":"61","author":"Mahomed","year":"2008","journal-title":"J Clinpathol."},{"key":"R4-20250616","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/00000478-200106000-00002","article-title":"Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases","volume":"25","author":"Robson","year":"2001","journal-title":"Am J Surg Pathol."},{"key":"R5-20250616","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1346-8138.2007.00324.x","article-title":"Eccrine porocarcinoma: clinical and pathological studies of 12 cases","volume":"34","author":"Shinohara","year":"2007","journal-title":"J Dermatol."},{"key":"R6-20250616","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2559.1984.tb02354.x","article-title":"Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryogenic antigen (CEA) in 65 primary skin carcinomas","volume":"8","author":"Heyderman","year":"1984","journal-title":"Histopathology"},{"key":"R7-20250616","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.0303-6987.2004.00147.x","article-title":"The diagnostic utility of p63, CK5\/6, CK7 and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas","volume":"31","author":"Qureshi","year":"2004","journal-title":"J Cutan Pathol."},{"key":"R8-20250616","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/modpathol.2010.46","article-title":"The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin","volume":"23","author":"Mahalingam","year":"2010","journal-title":"Mod Pathol."},{"key":"R9-20250616","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1468-3083.2010.03791.x","article-title":"Expression of stem cell markers nestin and cytokeratin 15 and 19 in cutaneous malignancies","volume":"25","author":"Abbas","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"R10-20250616","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/modpathol.2010.180","article-title":"Stem cell markers (cytokeratin 15, cytokeratin 19 and p63) in in situ and invasive cutaneous epithelial lesions","volume":"24","author":"Abbas","year":"2011","journal-title":"Mod Pathol."},{"key":"R11-20250616","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1034\/j.1600-0560.2001.281005.x","article-title":"The utility of cytokeratin 5\/6 in the recognition of cutaneous spindle cell squamous cell carcinoma","volume":"28","author":"Sigel","year":"2001","journal-title":"J Cutan Pathol."},{"key":"R12-20250616","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/978-3-642-78771-3_23","article-title":"Immunohistochemistry of eccrine poroma and porocarcinoma\u2014more than acrosyringeal tumors?","volume":"139","author":"Wollina","year":"1995","journal-title":"Recent Results Cancer Res."},{"key":"R13-20250616","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/DAD.0b013e31816de820","article-title":"Immunohistochemical distinction of cutaneous spindle cell carcinoma","volume":"30","author":"Morgan","year":"2008","journal-title":"Am J Dermatopathol."},{"key":"R14-20250616","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2559.2000.00999.x","article-title":"BerEP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin","volume":"37","author":"Beer","year":"2000","journal-title":"Histopathology"},{"key":"R15-20250616","doi-asserted-by":"crossref","first-page":"191","DOI":"10.5227\/skincancer.3.191","article-title":"The immunohistological distribution of CA19-9 in the normal human skin and human skin tumors","volume":"3","author":"Miyachi","year":"1988","journal-title":"Skin Cancer"},{"key":"R16-20250616","first-page":"1197","article-title":"Immunohistochemical studies on localization of CA19-9 in normal human skin and tumors of the sweat apparatus","volume":"98","author":"Horiuchi","year":"1998","journal-title":"Jpn J Dermatol."},{"key":"R17-20250616","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0190-9622(96)90105-X","article-title":"Metastasizing eccrine porocarcinoma: report of a case and review of the literature","volume":"35","author":"Huet","year":"1996","journal-title":"J Am Acad Dermatol."},{"key":"R18-20250616","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/cup.12632","article-title":"CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma","volume":"43","author":"Goto","year":"2016","journal-title":"J Cutan Pathol."},{"key":"R19-20250616","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI126185","article-title":"Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma","volume":"129","author":"Sekine","year":"2019","journal-title":"J Clin Invest."},{"key":"R20-20250616","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/cup.12043","article-title":"BerEP4 is widely expressed in tumors of the sweat apparatus: a source of potential diagnostic erroe","volume":"40","author":"Afshar","year":"2013","journal-title":"J Cutan Pathol."},{"key":"R21-20250616","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/DAD.0000000000000306","article-title":"GATA3 expression in normal skin and benign and malignant epidermal and cutaneous adnexal neoplasms","volume":"37","author":"Mertens","year":"2015","journal-title":"Am J Dermatopathol."},{"key":"R22-20250616","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/DAD.0000000000000634","article-title":"GATA3 and MYB expression in cutaneous adnexal neoplasms","volume":"39","author":"Pardal","year":"2017","journal-title":"Am J Dermatopathol."},{"key":"R23-20250616","first-page":"EC01","article-title":"The importance of cytokeratin 19 expression in the differentiation of basal cell carcinoma and trichoepithelioma","volume":"9","author":"Bedir","year":"2015","journal-title":"J Clin Diagn Res."},{"key":"R24-20250616","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1365-2133.2008.08731.x","article-title":"Increased expression of an epidermal stem cell marker, cytokeratin 19, in cutaneous squamous cell carcinoma","volume":"159","author":"Chen","year":"2008","journal-title":"Br J Dermatol."},{"key":"R25-20250616","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4137\/BIC.S11856","article-title":"Use of Ber-EP4 and epithelial specific antigen to differentiate clinical simulators of basal cell carcinoma","volume":"5","author":"Dasgeb","year":"2013","journal-title":"Biomark Cancer"},{"key":"R26-20250616","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41379-019-0206-z","article-title":"NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum","volume":"32","author":"Stevens","year":"2019","journal-title":"Mod Pathol."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T15:03:22Z","timestamp":1750086202000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000001901","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739822154.793589506","asserted-by":"object"}]},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}